Loading company…
Nuvation Bio Inc. develops and commercializes oncology medicines, including FDA-approved Taletrectinib (IBTROZI), for hard-to-treat cancers.
Founded in 2018 in New York, US, Nuvation Bio, Inc. develops and commercializes oncology medicines for difficult-to-treat cancers. Its FDA-approved Taletrectinib (IBTROZI) is sold directly to hospitals and clinics that treat cancer patients. The company's Series A round raised USD 275.00 mn led by Omega Funds, with participation from Aisling Capital and Fidelity Investments, and David Hung is CEO.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in